However, in innate lymphoid cells, these signaling pathways are not efficiently activated, leading to the sustained expression of IL-7R in the presence of IL-7.
OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20 th Congress of ECCO NANTES, France - January 28 2025, – 7:30am CET - OSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback